Author/Authors :
Shahbazian، Heshmatolah نويسنده Professor of Nephrology, Diabetes and CKD Research Centers, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, IR Iran , , Zafar Mohtashami، Azita نويسنده Assisstant Professor of Nephrology, Department of Internal Medicine, Shaheed Rahimi Hospital, Lorestan University of Medical Sciences, Khorramabad, IR Iran , , Belladi Musavi، Seyed Seifollah نويسنده Assisstant Professor of Nephrology, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, IR Iran , , Danesh، Mahnaz نويسنده Assisstant Professor of Nephrology, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, IR Iran , , Reza Lashkarara، Gholam نويسنده General Physician, MPH, Lorestan University of Medical Sciences, Khorramabad, IR Iran ,
Abstract :
Chronic kidney disease is a persistent disorder in kidney function. This is a progressive disorder characterized by arterial hypertension, glomerular hypertension, proteinuria and some other signs; controlling any of them can reduce the progression of chronic kidney disease. In chronic kidney disease, proteinuria is used as a measure for monitoring nephron injuries and its response to treatment. Angiotensin converting enzyme inhibitors and Angiotensin receptor blockers can reduce the progression of chronic kidney disease by inhibition of Renin-Angiotensin-Aldosterone system and reduction of glomerular pressure and controlling proteinuria. However, none of them can control plasma aldosterone level appropriately. Aldosterone produces Transforming growth factor-b (TGF-b), which induces proliferation of fibroblasts and glomerulosclerosis and accelerates chronic kidney disease. Aldosterone antagonist can increase useful effects of angiotensin-converting-enzyme inhibitor (ACEI) and Angiotensin receptor blockers (ARB) Drugs. The study was designed to assess the effects of spironolactone as the aldosterone antagonist combined with ACEI or ARB drugs to reduce proteinuria in chronic kidney disease to prevent its progression. This was a semi-experimental without control study. Eighty patients treated for at least two months with ACEI or ARB with uncontrolled proteinuria above 0.9g/dL were treated with 25mg/d spironolactone for two months. 24-hour urine protein and some other variables were measured at the beginning of the study, after two months treatment and one month after discontinuing the treatment. Administration of 25 mg/d spironolactone combined with ACEI or ARB for two months led to mean reduction of 24 h-urine protein from 2796.1 to 1857.4. No hyperkalemia or change in glomerular filtration rate occurred. One month after discontinuation of spironolactone, proteinuria returned to baseline level. Persistence of reduction in proteinuria in patients receiving ARBs was more than those taking ACEIs. Spironolactone combined with ACEIs or ARBs leads to reduction of proteinuria in chronic kidney disease and therefore reduction of progression of the disease.
